Dynamic Technology Lab Private Ltd Lowers Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Dynamic Technology Lab Private Ltd lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 71.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,352 shares of the biotechnology company’s stock after selling 28,807 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in BioCryst Pharmaceuticals were worth $86,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its holdings in shares of BioCryst Pharmaceuticals by 15.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 130,775 shares of the biotechnology company’s stock valued at $665,000 after acquiring an additional 17,091 shares in the last quarter. Tidal Investments LLC bought a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at $282,000. CWM LLC increased its holdings in shares of BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,772 shares in the last quarter. Diversified Trust Co increased its holdings in shares of BioCryst Pharmaceuticals by 18.0% during the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock valued at $153,000 after acquiring an additional 3,774 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of BioCryst Pharmaceuticals by 12.5% during the second quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company’s stock valued at $4,795,000 after acquiring an additional 86,249 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $7.19 on Wednesday. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -11.79 and a beta of 1.79. The stock’s 50-day simple moving average is $7.58 and its two-hundred day simple moving average is $7.32. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.19) earnings per share. As a group, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

BCRX has been the subject of several research analyst reports. JMP Securities lifted their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 6th. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.